December 20, 2023
2 min watch
Save
VIDEO: TRANSFORM-1, MANIFEST-2 studies probe combo therapies in myelofibrosis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.
Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute, discussed how the two studies unfolded – TRANSFORM-1 examined ruxolitinib plus navitoclax versus placebo, while MANIFEST-2 examined ruxolitinib plus pelabresib versus placebo.
“We are clearly moving as a field towards combination therapy for both frontline and relapse in refractory disease. So again, two incredibly important studies that are potentially practice changing,” Gerds said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Gerds reports serving in an advisory/consulting role for Bristol Myers Squibb, CTI Biopharma, GSK, Kartos/Telios, MorphoSys and PharmaEssentia.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.